Skip to main content
Clinical Trials/NCT05026710
NCT05026710
Completed
Not Applicable

Better Lithotripsy and Ureteroscopy Evaluation of Stenting (BLUES) A Pragmatic Randomized Multi-center Comparative Effectiveness Study

University of Michigan8 sites in 1 country224 target enrollmentDecember 2, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Renal Stone
Sponsor
University of Michigan
Enrollment
224
Locations
8
Primary Endpoint
Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) Scores of Pain-intensity at 7 to 10 Days
Status
Completed
Last Updated
6 months ago

Overview

Brief Summary

This multi-center trial is being completed to compare patient outcomes related to the Imajin silicone stent in comparison to non-silicone polyurethane stents after ureteroscopy.

Eligible participants will be enrolled and randomly assigned to receive the Imajin silicone stent or a non-silicone stent. In addition, the participants will complete questionnaires and have follow-up information collected (approximately 60 days after surgery).

The trial hypothesizes that a ureteral stent made of silicone, will have superior outcomes when compared to non-silicone stents.

Registry
clinicaltrials.gov
Start Date
December 2, 2021
End Date
August 21, 2024
Last Updated
6 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Khurshid Ghani

Associate Professor of Urology

University of Michigan

Eligibility Criteria

Inclusion Criteria

  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Diagnosed with unilateral renal and/or ureteral stones with the largest less than or equal to (≤)2.0 cm in size measured on abdominal x-ray, Ultrasound or computerized tomography (CT) scan
  • Renal stone defined as only renal location of stone(s).
  • Ureteral stone defined as ureteral only or ureteral and renal stone(s).
  • Planned unilateral ureteroscopy with stent placement without stent string.
  • Ability to take oral medication.
  • Ability and willingness to complete and adhere to survey questions and responses throughout study duration.

Exclusion Criteria

  • Known planned secondary or staged procedure
  • Presence of anatomical anomalies (for example (e.g.) solitary, horseshoe, fused crossed ectopia, pelvic kidney)
  • Presence of any prior urinary diversion (e.g. ileal conduit, orthotopic neobladder)
  • Presence of any indwelling ureteral stent prior to ureteroscopy
  • Presence of any indwelling nephrostomy tube prior to ureteroscopy
  • Ancillary ureteroscopy to treat residual fragments after percutaneous renal stone surgery
  • Renal stone located in calyceal diverticulum
  • No indication for stent placement (e.g. spontaneous passage)
  • Bladder stone location.
  • Pregnancy or lactation

Outcomes

Primary Outcomes

Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) Scores of Pain-intensity at 7 to 10 Days

Time Frame: Baseline, 7 to 10 days: Participants can fill out the survey at any time between 7 to 10 days after surgery.

This is a 3-item survey which participants select a response for each item from 1=no pain to 5=very severe for intensity of their pain. The sum of responses is then converted into a T-score that ranges from 36.3 to 81.8, with higher scores indicating worse pain intensity. Change is defined as the difference in T-score from baseline to 7-10 days after surgery.

Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) Scores of Pain-interference at 7 to 10 Days

Time Frame: Baseline, 7 to 10 days: Participants can fill out the survey at any time between 7 to 10 days after surgery.

This is a 6-item survey which participants select a response for each item from 1=not at all to 5=very much for how much pain interfered with their life. The sum of responses is then converted into a T-score that ranges from 41.0 to 78.3, with higher scores indicating worse pain interference. Change is defined as the difference in T-score from baseline to 7-10 days after surgery.

Secondary Outcomes

  • Change in National Institutes of Health (NIH) Lower Urinary Tract Dysfunction Research Network (LURN) Symptoms Index (SI)-10 Scores at 7 to 10 Days(Baseline, 7 to 10 days: Participants can fill out the survey at any time between 7 to 10 days after surgery.)
  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) Scores of Pain-intensity at 4 to 6 Weeks(Baseline, 4 to 6 weeks: Participants can fill out the survey at any time between 4 to 6 weeks after surgery.)
  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) Scores of Pain-interference at 4 to 6 Weeks(Baseline, 4 to 6 weeks: Participants can fill out the survey at any time between 4 to 6 weeks after surgery.)
  • Change in NIH LURN SI-10 Scores at 4 to 6 Weeks(: Baseline, 4 to 6 weeks: Participants can fill out the survey at any time between 4 to 6 weeks after surgery. Baseline, 4 to 6 weeks: Participants can fill out the survey at any time between 4 to 6 weeks after surgery.)
  • Composite Healthcare Utilization Metric Within 30 Days (WinRatio)(up to 30 days)
  • Abnormal Imaging Findings Within 60 Days(up to 60 days)
  • Stone-free Rates Within 60 Days(up to 60 days)

Study Sites (8)

Loading locations...

Similar Trials